Latest Radiosensitizer Stories

Sickle-shaped red blood cells target and destroy tumor cells and blood vessels The genetic mutation that causes sickle cell anemia also turns red blood cells into potent tumor killers and may offer a new way to treat some cancers that are resistant to existing treatments, according to research published January 9 in the open access journal PLOS ONE by David S. Terman of Jenomic Research Institute and colleagues from Duke University and other institutions. The mutation that causes sickle...

CARMEL, Calif., Jan. 9, 2013 /PRNewswire/ -- The genetic mutation that causes sickle cell anemia also turns red blood cells into potent tumor killers and may offer a new way to treat cancers that are resistant to existing treatments, according to research published January 9, 2013 in the open access journal PLOS ONE by David S. Terman of Jenomic Research Institute and colleagues from Duke University and other institutions. The mutation that causes sickle cell anemia to change the...

SEATTLE, Oct. 2, 2012 /PRNewswire/ -- Cell Therapeutics, Inc. ("CTI") (NASDAQ and MTA: CTIC) announced that OPAXIO (paclitaxel poliglumex) has been granted orphan-drug designation by the U.S Food and Drug Administration ("FDA") for the treatment of glioblastoma multiforme ("GBM"), a malignant brain cancer. Orphan designation was granted based on preliminary activity seen from phase 2 results of OPAXIO when added to standard therapy (temozolamide ("TMZ") plus radiation). In this...

ROCKVILLE, Md., July 30, 2012 /PRNewswire/ -- Radiation Control Technologies, Inc. (RCTI), a private development stage biopharmaceutical company developing RCT1938, a novel radiosensitizer that sensitizes tumor cells to killing by radiation while protecting healthy cells from radiation damage by inhibiting the synthesis of the novel target protein CD47, announced today that it has been granted an exclusive license to two patents from the National Institutes of Health (NIH). The...